Physician profile
Robert Lee Woodham
NPI 1578621223
$13,561.16
in general payments reported to CMS, 2019-2025
31 companies · $3,174 in 2025
The $3,174 reported for 2025 was more than what 95% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $900 · 2021: $1,627 · 2022: $1,739 · 2023: $2,415 · 2024: $2,484 · 2025: $3,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,044 · Education: $29.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,044.48 |
| Education | $29.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,089.11 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,620.38 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,533.97 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $1,122.54 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,106.99 | 2019-2025 | Invega Sustenna, Invega, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $1,008.31 | 2019-2025 | Trintellix |
| Corium, LLC | $966.19 | 2021-2025 | Azstarys |
| Abbvie INC. | $781.94 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $721.07 | 2019-2022 | |
| Alkermes, INC. | $506.34 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $497.39 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $246.12 | 2024-2025 | Auvelity |
| Eisai INC. | $192.11 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.75 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $137.70 | 2019-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $129.93 | 2019 | |
| Neos Therapeutics, LP | $121.52 | 2020-2025 | Adzenys Xr-Odt |
| Indivior INC. | $94.08 | 2019-2024 | Sublocade |
| Allergan, INC. | $86.91 | 2019-2020 | |
| Almatica Pharma LLC | $69.48 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $50.56 | 2019-2022 | |
| Bausch Health US, LLC | $49.72 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $46.35 | 2022-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $45.73 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $43.36 | 2024 | Quviviq |
| Adlon Therapeutics L.P. | $23.59 | 2021 | |
| Noven Therapeutics, LLC | $23.04 | 2020 | |
| Tris Pharma INC | $21.71 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $18.22 | 2022 | |
| Luye Pharma (USA) LTD. | $16.53 | 2025 | Erzofri Extended-Release |
| Arbor Pharmaceuticals, INC. | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Woodham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.